Autopsy report · NCT03993379
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Cause of deathFunding or business
“Sponsor's Decision”
Life of this trial
- Registered 6 months before it started.
- Ran for about 6 months before it stopped.
- 3 participants enrolled.
- Results were posted on the registry 1 year 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- CytomX Therapeutics
- Sponsor type
- Industry
- Conditions
- Solid Tumor; Unresectable or Metastatic Melanoma
- Interventions
- CX-072; Ipilimumab
- Participants
- 3
- Sites
- 27
- Countries
- Australia, Netherlands, South Korea, Spain, United States
Trials that died the same way
- A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease
“Sponsor decision”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.